Advertisement

Surgery pp 1787-1825 | Cite as

Liver Transplantation

  • Douglas W. Hanto
  • Scott R. Johnson
  • Seth J. Karp
  • Khalid Khwaja

Abstract

Chronic liver disease (CLD) is a major health problem in the United States, affecting millions of Americans and resulting in large health care expenditures and economic losses. The incidence of newly diagnosed CLD in the United States is 72.3 per 100,000 population.1 The most common etiologies of CLD include hepatitis C virus (HCV) (57%), alcohol (24%), nonalcoholic fatty liver disease (NAFLD) (9.1%), and hepatitis B virus (HBV) (4.4%). Approximately 3.9 million Americans (1.8 % of the population) have been infected with HCV, and 70% or 2.7 million have evidence of chronic infection based on detection of serum HCV RNA.2 Fortunately, the incidence of new infections is decreasing from a peak of 100 cases per 100,000 in the 1980s to 20 cases per 100,000 or 40,000 new infections annually currently. Because HCV is a chronic infection, however, the projections are for a fourfold increase between 1990 and 2015 in the number of individuals with a 20-year history of HCV infection13 (Fig. 85.1). This is important because of the increased risk in this population of life-threatening complications of CLD and the development of hepatocellular carcinoma (HCC). Estimates are that 14 million Americans (7.4% of the population) 18 years and older meet established criteria for alcohol abuse or dependence,1 and alcohol accounts for 28% of the deaths from CLD.

Keywords

Bile Duct Primary Biliary Cirrhosis Primary Sclerosing Cholangitis Orthotopic Liver Transplantation Biliary Atresia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227–242.PubMedCrossRefGoogle Scholar
  2. 2.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556–562.PubMedCrossRefGoogle Scholar
  3. 3.
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777–782.PubMedCrossRefGoogle Scholar
  4. 4.
    Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990–1998. Hepatology 2004;39:476–483.PubMedCrossRefGoogle Scholar
  5. 5.
    Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004;78:955–963.PubMedCrossRefGoogle Scholar
  6. 6.
    Shiffman ML, Saab S, Feng S, et al. Liver and intestine transplantation in the United States, 1995–2004. Am J Transplant 2006;6(part2):1170–1187.PubMedCrossRefGoogle Scholar
  7. 7.
    Hanto DW, Fishbein TM, Pinson CW, et al. Liver and intestine transplantation: summary analysis, 1994–2003. Am f Transplant 2005;5(4 pt 2):916–933.CrossRefGoogle Scholar
  8. 8.
    Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997;1:559–568, vi–vii.PubMedCrossRefGoogle Scholar
  9. 9.
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Tanaka H, Hiyama T, Tsukuma H, et al. Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical estimations from cross-sectional data. Jpn J Cancer Res 1994;85:485–490.PubMedGoogle Scholar
  12. 12.
    Curley SA, Izzo F, Gallipoli A, de Bellis M, Cremona F, Parisi V. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg 1995;222:375–380; discussion 380–383.PubMedCrossRefGoogle Scholar
  13. 13.
    Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Beresford TP, Turcotte JG, Merion R, et al. A rational approach to liver transplantation for the alcoholic patient. Psychosomatics 1990;31:241–254.PubMedGoogle Scholar
  15. 15.
    Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608–614.PubMedCrossRefGoogle Scholar
  16. 16.
    Heneghan MA, Sylvestre PB. Cholestatic diseases of liver transplantation. Semin Gastrointest Dis 2001;12:133–147.PubMedGoogle Scholar
  17. 17.
    Maor-Kendler Y, Batts KP, Burgart LJ, et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000;70:292–297.PubMedCrossRefGoogle Scholar
  18. 18.
    Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797–801.PubMedCrossRefGoogle Scholar
  19. 19.
    Freeman RB, Sanchez H, Lewis WD, et al. Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 1991;51:793–797.PubMedCrossRefGoogle Scholar
  20. 20.
    Rizzetto M, Recchia S, Salizzoni M. Liver transplantation in carriers of the HBsAg. J Hepatol 1991;13:5–7.PubMedCrossRefGoogle Scholar
  21. 21.
    O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104–111.PubMedCrossRefGoogle Scholar
  22. 22.
    Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998;227:841–850.PubMedCrossRefGoogle Scholar
  23. 23.
    Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Curr Gastroenterol Rep 1999;1:20–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003;3:999–1002.PubMedCrossRefGoogle Scholar
  25. 25.
    Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999;5:491–496.PubMedCrossRefGoogle Scholar
  26. 26.
    Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003;75(3 suppl):S41–S44.PubMedCrossRefGoogle Scholar
  27. 27.
    Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585–589.PubMedCrossRefGoogle Scholar
  28. 28.
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429–433.PubMedCrossRefGoogle Scholar
  29. 29.
    Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903–910.PubMedCrossRefGoogle Scholar
  30. 30.
    Rosenau J, Tillmann HL, Bahr MJ, et al. Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. Transplant Proc 2001;33:3637–3638.PubMedCrossRefGoogle Scholar
  31. 31.
    Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int 2005;17:746–758.PubMedCrossRefGoogle Scholar
  32. 32.
    Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741–748.PubMedCrossRefGoogle Scholar
  33. 33.
    Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528–1535.PubMedCrossRefGoogle Scholar
  34. 34.
    Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006;12:801–807.PubMedCrossRefGoogle Scholar
  35. 35.
    Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594–598.PubMedCrossRefGoogle Scholar
  36. 36.
    Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367–372.PubMedCrossRefGoogle Scholar
  37. 37.
    Burke A, Lucey MR. Non-alcoholic fatty liver disease, nonalcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004;4:686–693.PubMedCrossRefGoogle Scholar
  38. 38.
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 1990;11:74–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55:689–692.PubMedCrossRefGoogle Scholar
  40. 40.
    Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17(suppl):S186–S190.PubMedCrossRefGoogle Scholar
  41. 41.
    Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001;120:1281–1285.PubMedCrossRefGoogle Scholar
  42. 42.
    Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004;24:99–106.PubMedCrossRefGoogle Scholar
  43. 43.
    Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647–1654.PubMedCrossRefGoogle Scholar
  44. 44.
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–923.PubMedCrossRefGoogle Scholar
  45. 45.
    Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.PubMedCrossRefGoogle Scholar
  46. 46.
    Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32(4 pt 1):689–692.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924–933.PubMedCrossRefGoogle Scholar
  48. 48.
    Ahrendt SA, Pitt HA, Kalloo AN, et al. Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg 1998;227:412–423.PubMedCrossRefGoogle Scholar
  49. 49.
    Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995;22:451–457.PubMedCrossRefGoogle Scholar
  50. 50.
    Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995;117:146–155.PubMedCrossRefGoogle Scholar
  51. 51.
    Ismail T, Angrisani L, Powell JE, et al. Primary sclerosing cholangitis: surgical options, prognostic variables and outcome. Br J Surg 1991;78:564–567.PubMedCrossRefGoogle Scholar
  52. 52.
    Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993;68:874–879.PubMedGoogle Scholar
  53. 53.
    Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004;24:201–207.PubMedCrossRefGoogle Scholar
  54. 54.
    Onuchic LF, Furu L, Nagasawa Y, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexintranscription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002;70:1305–1317.PubMedCrossRefGoogle Scholar
  55. 55.
    Desmet VJ. Ludwig symposium on biliary disorders—part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998;73:80–89.PubMedCrossRefGoogle Scholar
  56. 56.
    Goss JA, Shackleton CR, Swenson K, et al. Orthotopic liver transplantation for congenital biliary atresia. An 11-year, single-center experience. Ann Surg 1996;224:276–284; discussion 284–287.PubMedCrossRefGoogle Scholar
  57. 57.
    Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999;5:29–34.PubMedCrossRefGoogle Scholar
  58. 58.
    Wall WJ, Adams PC. Liver transplantation for fulminant hepatic failure: North American experience. Liver Transpl Surg 1995;1:178–182.PubMedCrossRefGoogle Scholar
  59. 59.
    O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445.PubMedGoogle Scholar
  60. 60.
    Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003;31:299–305.PubMedCrossRefGoogle Scholar
  61. 61.
    Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King’s criteria. J Hepatol 1997;26:62–68.PubMedCrossRefGoogle Scholar
  62. 62.
    Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004;42:74–83.PubMedCrossRefGoogle Scholar
  63. 63.
    d’Annibale M, Piovanello P, Carlini P, et al. Epithelioid hemangioendothelioma of the liver: case report and review of the literature. Transplant Proc 2002;34:1248–1251.PubMedCrossRefGoogle Scholar
  64. 64.
    Madariaga JR, Marino IR, Karavias DD, et al. Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann Surg Oncol 1995;2:483–487.PubMedCrossRefGoogle Scholar
  65. 65.
    O’Grady JG, Poison RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988;207:373–379.PubMedGoogle Scholar
  66. 66.
    O’Grady JG. Treatment options for other hepatic malignancies. Liver Transpl 2000;6(6 suppl 2):S23–S29.PubMedCrossRefGoogle Scholar
  67. 67.
    Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994;20(1 pt 2):33S–40S.PubMedGoogle Scholar
  68. 68.
    Ismail T, Angrisani L, Gunson BK, et al. Primary hepatic malignancy: the role of liver transplantation. Br J Surg 1990;77:983–987.PubMedCrossRefGoogle Scholar
  69. 69.
    Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145–151.PubMedCrossRefGoogle Scholar
  70. 70.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.PubMedCrossRefGoogle Scholar
  71. 71.
    Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403.PubMedCrossRefGoogle Scholar
  72. 72.
    Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001;7:1023–1033.PubMedCrossRefGoogle Scholar
  73. 73.
    Orloff MJ, Daily PO, Orloff SL, Girard B, Orloff MS. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg 2000;232:340–352.PubMedCrossRefGoogle Scholar
  74. 74.
    Vons C, Smadja C, Bourstyn E, Szekely AM, Bonnet P, Franco D. Results of portal systemic shunts in Budd-Chiari syndrome. Ann Surg 1986;203:366–370.PubMedCrossRefGoogle Scholar
  75. 75.
    Hemming AW, Langer B, Greig P, Taylor BR, Adams R, Heathcote EJ. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996;171:176–180; discussion 180–181.PubMedCrossRefGoogle Scholar
  76. 76.
    Ringe B, Lang H, Oldhafer KJ, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology 1995;21:1337–1344.PubMedCrossRefGoogle Scholar
  77. 77.
    Moritz MJ, Jarrell BE, Munoz SJ, Maddrey WC. Regeneration of the native liver after heterotopic liver transplantation for fulminant hepatic failure. Transplantation 1993;55:952–954.PubMedGoogle Scholar
  78. 78.
    Chari RS, Collins BH, Magee JC, et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med 1994;331:234–237.PubMedCrossRefGoogle Scholar
  79. 79.
    Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225:484–491; discussion 491–494.PubMedCrossRefGoogle Scholar
  80. 80.
    Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217–222.PubMedCrossRefGoogle Scholar
  81. 81.
    Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307–313.PubMedCrossRefGoogle Scholar
  82. 82.
    Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004;127(5 suppl 1):S261–S267.PubMedCrossRefGoogle Scholar
  83. 83.
    Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients. A report from the A2LL consortium. Ann Surg 2005;242:314–325.PubMedGoogle Scholar
  84. 84.
    Menon KV, Nyberg SL, Harmsen WS, et al. MELD and other factors associated with survival after liver transplantation. Am J Transplant 2004;4:819–825.CrossRefGoogle Scholar
  85. 85.
    Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384–393; discussion 393–394.PubMedCrossRefGoogle Scholar
  86. 86.
    Forman LM, Lewis P, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889–896.PubMedCrossRefGoogle Scholar
  87. 87.
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28–S34.PubMedCrossRefGoogle Scholar
  88. 88.
    Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563–571.PubMedCrossRefGoogle Scholar
  89. 89.
    Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression ini patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006;12:1496–1503.PubMedCrossRefGoogle Scholar
  90. 90.
    Moore KA, Jones RM, Burrows GD. Quality of life and cognitive function of liver transplant patients: a prospective study. Liver Transpl 2000;6:633–642.PubMedCrossRefGoogle Scholar
  91. 91.
    Levy MF, Jennings L, Abouljoud MS, et al. Quality of life improvements at 1, 2, and 5 years after liver transplantation. Transplantation 1995;59:515–518.PubMedCrossRefGoogle Scholar
  92. 92.
    Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation 1993;55:807–813.PubMedCrossRefGoogle Scholar
  93. 93.
    Mor E, Klintmalm GB, Gonwa TA, et al. The use of marginal donors for liver transplantation: a retrospective study of 365 liver donors. Transplantation 1992;53:383–386.PubMedCrossRefGoogle Scholar
  94. 94.
    Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829–838.PubMedCrossRefGoogle Scholar
  95. 95.
    Gaffey MJ, Boyd JC, Traweek ST, et al. Predictive value of intraoperative biopsies and liver function tests for preservation injury in orthotopic liver transplantation. Hepatology 1997;25:184–189.PubMedCrossRefGoogle Scholar
  96. 96.
    D’Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991;51:157–163.PubMedGoogle Scholar
  97. 97.
    Cescon M, Grazi GL, Ercolani G, et al. Long-term survival of recipients of liver grafts from donors older than 80 years: is it achievable? Liver Transpl 2003;9:1174–1180.PubMedCrossRefGoogle Scholar
  98. 98.
    Wall WJ, Mimeault R, Grant DR, Bloch M. The use of older donor livers for hepatic transplantation. Transplantation 1998;49:377–381.Google Scholar
  99. 99.
    Hoofnagle JH, Lombardero M, Zetterman RK, et al. Donor age and outcome of liver transplantation. Hepatology 1996;24:89–96.PubMedCrossRefGoogle Scholar
  100. 100.
    Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005;5:549–557.PubMedCrossRefGoogle Scholar
  101. 101.
    Hanto DW, Fecteau AH, Alonso MH, Valente JF, Whiting JF. ABO-incompatible liver transplantation with no immunological graft losses using total plasma exchange, splenectomy, and quadruple immunosuppression: evidence for accommodation. Liver Transpl 2003;9:22–30.PubMedCrossRefGoogle Scholar
  102. 102.
    Verran D, Kusyk T, Painter D, et al. Clinical experience gained from use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003;9:500–505.PubMedCrossRefGoogle Scholar
  103. 103.
    Salizzoni M, Franchello A, Zamboni F, et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003;16:486–493.PubMedCrossRefGoogle Scholar
  104. 104.
    Johnson SR, Alexopoulos S, Curry M, Hanto DW. Primary nonfunction (PNF) in the MELD era: an SRTR database analysis. Am J Transplant 2007;7:1003–1009.PubMedCrossRefGoogle Scholar
  105. 105.
    Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783–790.PubMedCrossRefGoogle Scholar
  106. 106.
    Satterthwaite R, Ozgu I, Shidban H, et al. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997;64:432–435.PubMedCrossRefGoogle Scholar
  107. 107.
    Wachs M, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAG2, HBcABl, HBIgM2 organ donors. Transplantation 1995;59:230–234.PubMedCrossRefGoogle Scholar
  108. 108.
    Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003;9:S48–S51.PubMedCrossRefGoogle Scholar
  109. 109.
    Renz JF, Yersiz H, Reichert PR, et al. Split-liver transplantation: a review. Am J Transplant 2003;3:1323–1335.PubMedCrossRefGoogle Scholar
  110. 110.
    Barr ML, Belghiti J, Villamil FG, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 2006;81:1373–1387.PubMedCrossRefGoogle Scholar
  111. 111.
    Harms J, Bourquain H, Bartels M, et al. Surgical impact of computerized 3D Ct-based visualization in living donor liver transplantation. Surg Technol Int 2004;13:191–195.PubMedGoogle Scholar
  112. 112.
    Sahani D, D’souza R, Kadavigere R, et al. Evaluation of living liver transplant donors: method for precise anatomic definition by using a dedicated contrast-enhanced MR imaging protocol. Radiographics 2004;24:957–967.PubMedCrossRefGoogle Scholar
  113. 113.
    Iwasaki M, Takada Y, Hayashi M, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004;78:1501–1505.PubMedCrossRefGoogle Scholar
  114. 114.
    Trotter JF, Campsen J, Bak T, Wachs M, Forman L, Everson G, Kam I. Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation. Am J Transplant 2006;6:1882–1889.PubMedCrossRefGoogle Scholar
  115. 115.
    Lo CM, Chan KL, Fan ST, et al. Living donor liver transplantation: the Hong Kong experience. Tranplant Proc 1996;28:2390–2392.Google Scholar
  116. 116.
    Lo CM, Fan ST, Chan JKF, Wei W, Lo RJW, Lai CL. Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation 1996;62:696–698.PubMedCrossRefGoogle Scholar
  117. 117.
    Emond JC, Renz JF, Ferrell LD, et al. Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg 1996;224:544–552; discussion 552–554.PubMedCrossRefGoogle Scholar
  118. 118.
    Gonzalez Chamorro A, Loinaz Segurola C, Moreno Gonzalez E, et al. Graft mass and volume calculation in living related donors for liver transplantation. Hepatogastroenterology 1998;45:510–513.PubMedGoogle Scholar
  119. 119.
    Urata K, Kawasaki S, Matsunami H, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995;21:1317–1321.PubMedCrossRefGoogle Scholar
  120. 120.
    Pomfret EA, Pomposelli JJ, Gordon FD, et al. Liver regeneraton and surgical outcome in donors of right-lobe liver grafts. Transplantation 2003;76:5–10.PubMedCrossRefGoogle Scholar
  121. 121.
    Emre S, Schwartz ME, Miller CM. The donor operation. In: Busuttil RW, Klintmalm GB, eds. Transplantation of the Liver. Philadelphia: Saunders; 1996:392–404.Google Scholar
  122. 122.
    Nakazato PZ, Concepcion W, Bry W, et al. Total abdominal evisceration: an en bloc technique for abdominal organ harvesting. Surgery 1992;111:37–47.PubMedGoogle Scholar
  123. 123.
    Boggi U, Vistoli F, Del Chiaro M, et al. A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation. Surgery 2004;135:629–641.PubMedCrossRefGoogle Scholar
  124. 124.
    Abt PL, Desai NM, Crawford MD, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004;239:87–92.PubMedCrossRefGoogle Scholar
  125. 125.
    Reich DJ, Munoz SJ, Rothstein KD, et al. Controlled non-heart-beating donor liver transplantation. Transplantation 2000;70:1159–1166.PubMedCrossRefGoogle Scholar
  126. 126.
    D’Alessandro AM, Hoffmann RM, Knechtle SJ, et al. Liver transplantation from controlled non-heart-beating donors. Surgery 2000;128:579–588.PubMedCrossRefGoogle Scholar
  127. 127.
    Casavilla A, Ramirez C, Shapiro R, et al. Experience with liver and kidney allografts from non-heart-beating donors. Transplantation 1995;59:197–203.PubMedCrossRefGoogle Scholar
  128. 128.
    Johnson SR, Pavlakis M, Khwaja K, et al. Intensive care unit extubation does not preclude extrarenal organ recovery from donors after cardiac death. Transplantation 2005;80:1244–1250.PubMedCrossRefGoogle Scholar
  129. 129.
    Bismuth H, Houssin D. Reduced-size orthotopic liver graft in hepatic transplantation in children. Surgery 1984;95:367–370.PubMedGoogle Scholar
  130. 130.
    Broelsch CE, Emond JC, Thistlethwaite JR, Rouch DA, Whiting-ton PF, Lichtor JL. Liver transplantation with reduced-size donor organs. Transplantation 1988;45:519–524.PubMedCrossRefGoogle Scholar
  131. 131.
    Couinaud C. Le Foie. Etudes Anatomiques et Cirurgicales. Paris: Masson; 1957.Google Scholar
  132. 132.
    Humar A, Khwaja K, Sielaff TD, Lake JR, Payne WD. Split-liver transplants for two adult recipients: technique of preservation of the vena cava with the right lobe graft. Liver Transpl 2004;10:153–155.PubMedCrossRefGoogle Scholar
  133. 133.
    Broelsch CE, Whitington PF, Emond JC, et al. Liver transplantation in children from living related donors. Surgical techniques and results. Ann Surg 1991;214:428–437; discussion 437–439.PubMedCrossRefGoogle Scholar
  134. 134.
    Bak T, Wachs M, Trotter J, et al. Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience. Liver Transpl 2001;7:680–686.PubMedCrossRefGoogle Scholar
  135. 135.
    Wachs ME, Bak TE, Karrer FM, et al. Adult living donor liver transplantation using a right hepatic lobe. Transplantation 1998;66:1313–1316.PubMedCrossRefGoogle Scholar
  136. 136.
    Lo CM, Fan ST, Liu CL, et al. Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg 2004;240:151–158.PubMedCrossRefGoogle Scholar
  137. 137.
    Shaw BWJ, Martin DJ, Marquez JM, et al. Venous bypass in clinical liver transplantation. Ann Surg 1984;200:524–534.PubMedCrossRefGoogle Scholar
  138. 138.
    Grande L, Rimola A, Cugat E, et al. Effect of venovenous bypass on perioperative renal function in liver transplantation: results of a randomized, controlled trial. Hepatology 1996;23:1418–1428.PubMedCrossRefGoogle Scholar
  139. 139.
    Wall WJ, Grant DR, Duff JH, Kutt JL, Ghent CN, Block MS. Liver transplantation without venous bypass. Transplantation 1987;43:56–61.PubMedCrossRefGoogle Scholar
  140. 140.
    Johnson SR, Marterre WF, Alonso MH, Hanto DW. A percutaneous technique for venovenous bypass in orthotopic cadaver liver transplantation and comparison with the open technique. Liver Transplant Surg 1996;2:354–361.CrossRefGoogle Scholar
  141. 141.
    Rouch DA, Emond JC, Thistlewaite JRJ, Mayes JT, Broelsch CE. Choledochostomy without a T tube or internal stent in transplantation of the liver. Surg Gynecol Obstet 1990;170:239–244.PubMedGoogle Scholar
  142. 142.
    Vougas V, Rela M, Gane E, et al. A prospective randomised trial of bile duct reconstruction at liver transplantation: T tube or no T tube? Transpl Int 1996;9:392–395.PubMedCrossRefGoogle Scholar
  143. 143.
    Busque S, Esquivel CO, Concepcion W, So SKS. Experience with the piggyback technique without caval occlusion in adult orthotopic liver transplantation. Transplantation 1998;65:77–82.PubMedCrossRefGoogle Scholar
  144. 144.
    Andorno E, Genzone A, Morelli N, et al. One liver for two adults: in situ split liver transplantation for two adult recipients. Transplant Proc 2001;33:1420–1422.PubMedCrossRefGoogle Scholar
  145. 145.
    Azoulay D, Castaing D, Adam R, et al. Split-liver transplantation for two adult recipients: feasibility and long-term outcomes. Ann Surg 2001;233:565–574.PubMedCrossRefGoogle Scholar
  146. 146.
    Egawa H, Inomata Y, Uemoto S, et al. Hepatic vein reconstruction in 152 living-related donor liver transplantation patients. Surgery 1997;121:250–257.PubMedCrossRefGoogle Scholar
  147. 147.
    Emond JC. Clinical application of living-related liver transplantation. Gastroenterol Clin North Am 1993;22:301–315.PubMedGoogle Scholar
  148. 148.
    Inomoto T, Nishizawa F, Sasaki H, et al. Experiences of 120 microsurgical reconstructions of hepatic artery in living related liver transplantation. Surgery 1996;119:20–26.PubMedCrossRefGoogle Scholar
  149. 149.
    Ikegami T, Kawasaki S, Matsunami H, et al. Should all hepatic arterial branches be reconstructed in living-related liver transplantation? Surgery 1996;119:431–436.PubMedCrossRefGoogle Scholar
  150. 150.
    Kubota T, Togo S, Sekido H, et al. Indications for hepatic vein reconstruction in living donor liver transplantation of right liver grafts. Tranplant Proc 2004;36:2263–2266.CrossRefGoogle Scholar
  151. 151.
    Humar A, Khwaja K, Sielaff TD, Lake JR, Payne WD. Technique of split-liver transplant for two adult recipients. Liver Transpl 2002;8:725–729.PubMedCrossRefGoogle Scholar
  152. 152.
    Marcos A, Killackey M, Orloff MS, Mieles L, Bozorgzadeh A, Tan HP. Hepatic arterial reconstruction in 95 adult right lobe living donor liver transplants: evolution of anastomotic technique. Liver Transpl 2003;9:570–574.PubMedCrossRefGoogle Scholar
  153. 153.
    Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Stein-muller T, Neuhaus P. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl 2003;9:612–620.PubMedCrossRefGoogle Scholar
  154. 154.
    Tzakis AG, Gordon RD, Shaw BW Jr, Iwatsuki S, Starzl TE. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation 1985;40:667–671.PubMedCrossRefGoogle Scholar
  155. 155.
    Langnas AN, Marujo W, Stratta RJ, Wood RP, Li SJ, Shaw BW. Hepatic allograft rescue following arterial thrombosis. Role of urgent revascularization. Transplantation 1991;51:86–90.PubMedCrossRefGoogle Scholar
  156. 156.
    Abbasoglu O, Levy MF, Vodapally MS, et al. Hepatic artery stenosis after liver transplantation—incidence, presentation, treatment, and long term outcome. Transplantation 1997;63:250–255.PubMedCrossRefGoogle Scholar
  157. 157.
    Sheiner PA, Varma CV, Guarrera JV, et al. Selective revascularization of hepatic artery thromboses after liver transplantation improves patient and graft survival. Transplantation 1997;64:1295–1299.PubMedCrossRefGoogle Scholar
  158. 158.
    Cavallari A, Vivarelli M, Bellusci R, Jovine E, Mazziotti A, Rossi C. Treatment of vascular complications following liver transplantation: multidisciplinary approach. Hepatogastroenterology 2001;48:179–183.PubMedGoogle Scholar
  159. 159.
    Vivarelli M, Cucchetti A, La Barba G, et al. Ischemic arterial complications after liver transplantation in the adult: multivariate analysis of risk factors. Arch Surg 2004;139:1069–1074.PubMedCrossRefGoogle Scholar
  160. 160.
    Cotroneo AR, Di Stasi C, Cina A, et al. Stent placement in four patients with hepatic artery stenosis or thrombosis after liver transplantation. J Vasc Interv Radiol 2002;13:619–623.PubMedCrossRefGoogle Scholar
  161. 161.
    Valente JF, Alonso MH, Weber FL, Hanto DW. Late hepatic artery thrombosis in liver allograft recipients is associated with intrahepatic biliary necrosis. Transplantation 1996;61:61–65.PubMedCrossRefGoogle Scholar
  162. 162.
    Orons PD, Sheng R, Zajko AB. Hepatic artery stenosis in liver transplant recipients: prevalence and cholangiographic appearance of associated biliary complications. AJR Am J Roentgenol 1995;165:1145–1149.PubMedGoogle Scholar
  163. 163.
    Narumi S, Osorio RW, Freise CE, Stock PG, Roberts JP, Ascher NL. Hepatic artery pseudoaneurysm with hemobilia following angioplasty after liver transplantation. Clin Transplant 1998;12:508–510.PubMedGoogle Scholar
  164. 164.
    Fukuzawa K, Schwartz ME, Katz E, et al. The arcuate ligament syndrome in liver transplantation. Transplantation 1993;56:223–224.PubMedCrossRefGoogle Scholar
  165. 165.
    Jurim O, Shaked A, Kiai K, Millis JM, Colquhoun SD, Busuttil RW. Celiac compression syndrome and liver transplantation. Ann Surg 1993;218:10–12.PubMedCrossRefGoogle Scholar
  166. 166.
    Moser MA, Wall WJ. Management of biliary problems after liver transplantation. Liver Transpl 2001;7(11 suppl 1):S46–S52.PubMedCrossRefGoogle Scholar
  167. 167.
    Thethy S, Thomson B, Pleass H, et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant 2004;18:647–653.PubMedCrossRefGoogle Scholar
  168. 168.
    Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651–663.PubMedCrossRefGoogle Scholar
  169. 169.
    Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003;75:1659–1663.PubMedCrossRefGoogle Scholar
  170. 170.
    Scatton O, Meunier B, Cherqui D, et al. Randomized trial of choledochocholedochostomy with or without a T tube in orthotopic liver transplantation. Ann Surg 2001;233:432–437.PubMedCrossRefGoogle Scholar
  171. 171.
    Shimoda M, Saab S, Morrisey M, et al. A cost-effectiveness analysis of biliary anastomosis with or without T-tube after orthotopic liver transplantation. Am J Transplant 2001;1:157–161.PubMedCrossRefGoogle Scholar
  172. 172.
    Thuluvath PJ, Atassi T, Lee J. An endoscopic approach to biliary complications following orthotopic liver transplantation. Liver Int 2003;23:156–162.PubMedCrossRefGoogle Scholar
  173. 173.
    Pfau PR, Kochman ML, Lewis JD, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc 2000;52:55–63.PubMedCrossRefGoogle Scholar
  174. 174.
    Pomfret EA. Early and late complications in the right-lobe adult living donor. Liver Transpl 2003;9(10 suppl 2):S45–S49.PubMedCrossRefGoogle Scholar
  175. 175.
    Trotter JF, Adam R, Lo CM, Kenison J. Documented deaths of hepatic lobe donors for living donor transplantation. Liver Transpl 2006;12:1485–1488.PubMedCrossRefGoogle Scholar
  176. 176.
    Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-h post dose levels (C2). Transplantation 2002;73:953–969.PubMedCrossRefGoogle Scholar
  177. 177.
    Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004;77:1209–1214.PubMedCrossRefGoogle Scholar
  178. 178.
    Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001;6:473–484.CrossRefGoogle Scholar
  179. 179.
    Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation. Beyond calcineurin inhibitors. Liver Transpl 2005;11:267–280.PubMedCrossRefGoogle Scholar
  180. 180.
    Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883–889.PubMedCrossRefGoogle Scholar
  181. 181.
    Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005;5(4 pt 2):874–886.PubMedCrossRefGoogle Scholar
  182. 182.
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003;75:1396–1399.PubMedCrossRefGoogle Scholar
  183. 183.
    Greig P, Lilly L, Scudamore C, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003;9:587–595.PubMedCrossRefGoogle Scholar
  184. 184.
    Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001;7:343–351.PubMedCrossRefGoogle Scholar
  185. 185.
    The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110–1115.CrossRefGoogle Scholar
  186. 186.
    European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423–428.CrossRefGoogle Scholar
  187. 187.
    Wiesner RH, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442–450.PubMedCrossRefGoogle Scholar
  188. 188.
    Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo AP, Bollinger RR. Hepatic transplantation into sensitized recipients: demonstration of hyperacute rejection. Transplantation 1987;43:8–12.PubMedCrossRefGoogle Scholar
  189. 189.
    Hanto DW, Snover DC, Noreen HJ, et al. Hyperacute rejection of a human orthotopic liver allograft in a presensitized recipient. Clin Transplant 1987;1:304–310.Google Scholar
  190. 190.
    Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988;132:489–502.PubMedGoogle Scholar
  191. 191.
    Ratner L, Phelan D, Brunt EM, Mohanakumar T, Hanto DW. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. 1993;55:814–819.Google Scholar
  192. 192.
    Hanto DW. A 50-year-old man with hepatitis C and cirrhosis needing liver transplantation. JAMA 2003;290:3238–3246.PubMedCrossRefGoogle Scholar
  193. 193.
    Neumann UP, Lang M, Moldenhauer A, et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001;71:1163–1168.PubMedCrossRefGoogle Scholar
  194. 194.
    Eid A, Moore SB, Wiesner RH, DeGoey SR, Nielson A, Krom RAF. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. Transplantation 1990;50:331–334.PubMedGoogle Scholar
  195. 195.
    Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638–645.PubMedCrossRefGoogle Scholar
  196. 196.
    Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: practice and trends. American Journal of Transplantation 2004;4(suppl 9):38–53.PubMedCrossRefGoogle Scholar
  197. 197.
    Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658–663.CrossRefGoogle Scholar
  198. 198.
    Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000;31:792–799.PubMedCrossRefGoogle Scholar
  199. 199.
    Volpin R, Angeli P, Galioto A, et al. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl 2002;8:527–534.PubMedCrossRefGoogle Scholar
  200. 200.
    Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med 1998;338:1741–1751.PubMedCrossRefGoogle Scholar
  201. 201.
    Whiting JF, Rossi SJ, Hanto DW. Infectious complications after OKT3 induction in liver transplantation. Liver Transplant Surg 1997;3:563–570.CrossRefGoogle Scholar
  202. 202.
    Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995;21:1328–1336.PubMedCrossRefGoogle Scholar
  203. 203.
    Rayes N, Seehofer D, Theruvath T, et al. Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double-blind trial. Am J Transplant 2005;5:125–130.PubMedCrossRefGoogle Scholar
  204. 204.
    Trotter JF, Wallack A, Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transplant Infect Dis 2003;5:174–180.CrossRefGoogle Scholar
  205. 205.
    Gane E, Saliba F, Valdecasas FJC, O’Grady J, Pescovitz MD, Lyman S. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729–1733.PubMedCrossRefGoogle Scholar
  206. 206.
    Couchoud C, Chucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998;65:64-1–647.CrossRefGoogle Scholar
  207. 207.
    Winston DJ, Busuttil RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004;77:305–308.PubMedCrossRefGoogle Scholar
  208. 208.
    Hanto DW. Classification of Epstein-Barr virus-associated post-transplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995;46:381–394.PubMedCrossRefGoogle Scholar
  209. 209.
    Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001;3:88–96.PubMedCrossRefGoogle Scholar
  210. 210.
    Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBVPTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517–1525.PubMedCrossRefGoogle Scholar
  211. 211.
    Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289–1293.PubMedCrossRefGoogle Scholar
  212. 212.
    Savoldo B, Rooney CM, Quiros-Tejeira E, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005;5:566–572.PubMedGoogle Scholar
  213. 213.
    Levitsky J, Kalil A, Meza JL, Hurst GE, Freifeld A. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl 2005;11:320–325.PubMedCrossRefGoogle Scholar
  214. 214.
    Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317–1323.PubMedCrossRefGoogle Scholar
  215. 215.
    Rabkin JM, Orloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000;2000:426–430.CrossRefGoogle Scholar
  216. 216.
    Paya CV. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001;33(suppl 1):S47–S52.PubMedCrossRefGoogle Scholar
  217. 217.
    Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003;75:2023–2029.PubMedCrossRefGoogle Scholar
  218. 218.
    Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–1402.PubMedCrossRefGoogle Scholar
  219. 219.
    Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. Ann Internal Med 1999;131:729–737.Google Scholar
  220. 220.
    Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrion S, Barrios C. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996;174:583–688.PubMedGoogle Scholar
  221. 221.
    Sharpe MD, Ghent C, Grant D, et al. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003;76:977–983.PubMedCrossRefGoogle Scholar
  222. 222.
    Randall HB, Wachs ME, Somberg KA, et al. The use of the T tube after orthotopic liver transplantation. Transplantation 1996;61:258–261.PubMedCrossRefGoogle Scholar
  223. 223.
    Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611–620.PubMedCrossRefGoogle Scholar
  224. 224.
    Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003;75:229–233.PubMedCrossRefGoogle Scholar
  225. 225.
    Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470.PubMedCrossRefGoogle Scholar
  226. 226.
    Humar A, Sielaff RT, Lake JR, Payne WD. Split liver transplant for two adult recipients—evolution of the surgical procedure. Paper presented at: American Transplant Congress 2004; Boston; May 15–19, 2004.Google Scholar
  227. 227.
    New York State Committee on Quality Improvements in Living Liver Donation. A report to the New York State Transplant Council and New York State Department of Health. New York State Department of Health, Albany, NY; December 2002.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Douglas W. Hanto
    • 1
    • 2
  • Scott R. Johnson
    • 1
    • 3
  • Seth J. Karp
    • 1
    • 2
  • Khalid Khwaja
    • 1
    • 3
  1. 1.Department of Surgery, Harvard Medical SchoolBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Division of TransplantationBeth Israel Deaconess Medical CenterBostonUSA
  3. 3.Beth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations